Orlistat

Molecular Structure:

Molecular Formula: C₂₉H₅₃NO₅
Molecular Weight: 495.73
CAS NO: 96829-58-2
H bond acceptors: 6
H bond donors: 1
Freely Rotating Bonds: 23
Polar Surface Area: 72.91 Å²
Index of Refraction: 1.469
Molar Refractivity: 141.57 cm³
Molar Volume: 507.5 cm³
Surface Tension: 35.6 dyne/cm
Density: 0.976 g/cm³
Flash Point: 326.3 °C
Melting Point: <50 °C
Enthalpy of Vaporization: 91.36 kJ/mol
Boiling Point: 615.9 °C at 760 mmHg
Vapour Pressure: 4.23E-15 mmHg at 25°C
Storage temp: 2-8°C
Solubility: DMSO: 19 mg/mL
Appearance: Off-White Solid
IUPAC Name: [(2S)-1-[(2S,3S)-3-Hexyl-4-oxooxetan-2-yl]tridecan-2-yl] (2S)-2-formamido-4-methylpentanoate 
Synonyms of Orlistat (CAS NO.96829-58-2): (-)-Tetrahydrolipstatin ; Alli ; L-Leucine, N-formyl-, 1-((3-hexyl-4-oxo-2-oxetanyl)methyl)dodecyl ester, (2S-(2alpha(R*),3beta))- ; N-Formyl-L-leucine, ester with (3S,4S)-3-hexyl-4-((2S)-2-hydroxytridecyl)-2-oxetanone ; Orlipastat ; Orlipastatum ; Orlipastatum [INN-Latin] ; Ro 18-0647/002 ; Tetrahydrolipstatin ; UNII-95M8R751W8 ; Xenical ; L-Leucine, N-formyl-, (1S)-1-(((2S,3S)-3-hexyl-4-oxo-2-oxetanyl)methyl)dodecyl ester
Product Categories of Orlistat (CAS NO.96829-58-2): Pharmaceutical Raw Materials;Miscellaneous
Biochemicals;API;Antiobesity Agent;Chiral Reagents;Intermediates & Fine Chemicals;Pharmaceuticals

 Orlistat (CAS NO.96829-58-2) is a drug designed to treat obesity. It is mainly used for preventing the absorption of fats from the human diet, thereby reducing caloric intake. Besides, it is intended for use in conjunction with a physician-supervised reduced-calorie diet.

WGK Germany: 3
RTECS: OH3167600

Side effects of Orlistat (CAS NO.96829-58-2): The primary side effects of the drug are gastrointestinal-related, and include steatorrhea (oily, loose stools with excessive flatus due to unabsorbed fats reaching the large intestine), fecal incontinence and frequent or urgent bowel movements.